Prestige Brands Holdings

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PBH reports record fiscal 2023 results, addresses inflation challenges

PBH's strong fiscal 2023 performance was highlighted, but challenges from inflation and foreign currency headwinds were acknowledged. The company is focused on leveraging opportunities for growth and remains committed to its long-term goals.

PBH reports resilient Q1 performance, anticipates high single-digit Q2 growth

PBH's Q1 performance demonstrated resilience with strong sales and margin improvements. While facing challenges in EBITDA and gross margin, the company's strategic focus on brand growth, debt reduction, and share buyback program positions it well for future opportunities. With a reaffirmed full-year outlook and anticipated Q2 growth, PBH remains focused on sustainable growth and financial discipline.

Prestige Brands reports solid Q3 earnings, eyes growth opportunities

Prestige Brands Holdings (PBH) delivered a solid performance in Q3 2023, driven by strong revenue growth, profitability, and strategic financial management.
While facing challenges such as gross margin decline and industry-wide inflationary pressures, the company remains focused on cost management and pricing strategies to sustain growth.
With opportunities for revenue growth, operational efficiency, and strategic planning in fiscal 2024, Prestige Brands is well-positioned for continued success and value creation.

Prestige Brands Holdings reports record fiscal '23 results and outlines growth strategies for fiscal '24

Prestige Brands Holdings delivered strong financial results in fiscal '23, with robust revenue growth and adjusted EPS. The company is focused on maintaining margins, reducing leverage, and capitalizing on growth opportunities in key segments. Management's strategic outlook for fiscal '24 includes revenue projections, EPS targets, and a commitment to disciplined capital allocation.

Prestige Brands Holdings (PBH) surpasses Q1 expectations amidst challenges

PBH's Q1 performance exceeded expectations with strong organic sales growth and improved gross margin despite cost pressures.
While facing challenges from cost increases and debt levels, PBH maintains a solid financial position with strong cash flow.
Opportunities lie in sustained revenue growth, market expansion, and operational efficiency enhancements for PBH in the coming quarters.

Prestige Brands reports robust Q2 results, eyes international growth

Prestige Brands Holdings delivered a solid performance in Q2, driven by strong sales, EPS growth, and debt reduction.
While facing challenges in North America and margin pressure, the company's international growth and e-commerce focus present opportunities for future expansion.
Maintaining a healthy financial position with strong cash flow and reaffirming full-year outlook underscores Prestige Brands' stability and growth potential.
Strategic management of expenses and leveraging brand success will be crucial for sustained growth and profitability in the competitive consumer goods market.

Prestige Brands Holdings reports solid Q3 performance and eyes growth

Prestige Brands Holdings delivered a strong Q3 performance with revenue exceeding expectations and a focus on maintaining market share and brand differentiation.
The company's financial discipline led to debt reduction and healthy free cash flow, while challenges include inventory coverage issues and evaluating M&A opportunities.
Opportunities for growth include exploring potential M&A deals, focusing on long-term financial targets, and capitalizing on international and North American segment growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the North American OTC Healthcare and International OTC Healthcare segments. The North American and International OTC Healthcare segments manage the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prestige Consumer Healthcare (PBH) Earnings Expected to Grow: What to Know Ahead of Q4 Release

TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on Tuesday, May 14, 2024 after the market close. The Company will host a conference call to discuss the results the following morning, May 15th, at 8:30 a.m. ET.

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results

The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.

Here's Why You Should Retain Prestige Consumer (PBH) Stock Now

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock

The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag

Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.

Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Prestige Consumer Healthcare (PBH) is a Strong Momentum Stock

Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term

Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.

Reasons to Retain Prestige Consumer (PBH) Stock for Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Prestige Consumer Healthcare (PBH) is a Top Momentum Stock for the Long-Term

Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.

Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands

Prestige Consumer Healthcare Inc. (PBH) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Prestige Consumer Healthcare (PBH) Reports Q3 Earnings: What Key Metrics Have to Say

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.04 per share a year ago.

Prestige Consumer Healthcare (PBH) Surpasses Q3 Earnings and Revenue Estimates

TARRYTOWN, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2023.

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results

Boston Scientific

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

PBH vs. BSX: Which Stock Should Value Investors Buy Now?

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredient in any Ting® Antifungal Spray products, the review showed that unexpected levels of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid (either before or after these batch codes) and no other Ting® Antifungal Spray Liquid products are in the scope of this recall and may continue to be used by consumers safely and as intended.

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene

Prestige Consumer Healthcare (PBH) Reports Next Week: What Awaits?

Quest Diagnostics

Hologic

Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.

3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?

PBH or BSX: Which Is the Better Value Stock Right Now?

TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third quarter earnings release on Thursday, February 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results

Haemonetics

Neogen

Royal Philips

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.

4 Medical Product Stocks to Buy Amid Industry Challenges

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

PBH vs. BSX: Which Stock Is the Better Value Option?

Investors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio.

Reasons to Buy Prestige Consumer (PBH) Stock for Now

TARRYTOWN, N.Y., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level. While benzene is not an ingredient in any Americaine® 20% Benzocaine Topical Anesthetic Spray products, a recent review by our manufacturer and their third-party lab found that a sample from one lot of the product showed a low level of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of Americaine® 20% Benzocaine Topical Anesthetic Spray (either before or after this batch code) are in the scope of this recall and may continue to be used by consumers safely and as intended.

News for Prestige Brands Holdings Stock (PBH)